Comparative assessment for Biosimilars and Abbreviated New Drug Application (ANDA)

During manufacturing biosimilars and ANDA, comparative assessment studies are essential for ensuring that any change in manufacturing process does not have any adverse impact on the quality, safety or efficacy of a biologic product. The comparability studies are also an essential pre-requisite for providing analytical confirmation that the drug product or substance has similar quality attributes pre and post changes in manufacturing process.